The Science

Regulating cell metabolism to develop disease modifying therapeutics in immunoinflammation & immunooncology.

The Science of Sitryx

Focus on immunometabolism

The field of immunometabolism is a rapidly emerging and exciting area of investigation into the role of intracellular metabolic pathways in immune cells.

Changes to these pathways are pivotal in the development of severe diseases, including autoimmune conditions and cancer.

Sitryx is building a broad and differentiated pipeline by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.

Intervening in cell metabolism

Metabolic changes within cells of the immune system can drive the pathology of a disease. By intervening in cell metabolism, inflammation and tissue damage can be reversed and resolved, leading to better patient outcomes.

Metabolic changes can contribute to pathology

  • Normal Tissue
  • Acute Inflammation
  • Chronic Inflammation
  • Tissue Damage and Fibrosis

← Metabolic intervention can reverse changes

Broad-based impact to resolve disease

Most modern anti-inflammatory and oncology drugs intervene at a particular point causing immunosuppression with limited results. Changing the state of different combinations of immune cells can have a much more wide-ranging impact to potentially resolve inflammation.

Blocking Cytokines

Blocking cytokines at one particular point results in targeted immunosuppression and resolution of disease in a limited subset of patients.

Targeted Metabolic Intervention

Targeted metabolic intervention can shift cells to a non-inflammatory pro-resolution state, offering the potential for a broader population of patients to achieve disease remission.

Different diseases targeted through specific cell types

Different cells of the immune system are implicated in different diseases and hence different groups of cells of the immune system can be targeted by intervening at particular points of metabolism.

By targeting a range of points of metabolic control, Sitryx can build a portfolio across a range of diseases.

Augment Inhibit
Inflammatory macrophage
Pan-Inflamm T-cell
Th1 cell
Th17 cell
T Reg cell
B cell
Anti-tumour T-cell
Tumour assoc. T Reg
Profile 1Psoriasis, MS, GVHD, SLE, refractory RA, fibrosis
Profile 2Psoriasis, MS, GVHD, SLE
Profile 3IL-17 and antibody-mediated diseases
Profile 4Antibody-mediated diseases, MS, GVHD
Profile 5IL-17 mediated-diseases
Profile 6TBD

The patient perspective

Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, leading to better outcomes.

Offering the potential for a broader population of patients to achieve remission in a range of severe diseases in immunology and oncology.